Ranbaxy's revenue growth to be led by Terapia acquisition

42231 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy's revenue growth to be led by Terapia acquisition

Pharma space's biggie, Ranbaxy will come out with results in a little while from now. CNBC-TV18's research Sunita Nagpal discusses what one can expect form it.

Post your opinion here

 

0

Tweet

Share on Tumblr

Excerpts from Markets Midday on CNBC-TV18 Watch the full show » ALSO READ News and Notices about Ranbaxy Labs See interviews with Ranbaxy Labs Management See what other Experts & Brokerages are saying about Ranbaxy Labs See previous Results of Ranbaxy Labs Ranbaxy Labs BSE | NSE 25/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Pharma space's biggie, Ranbaxy will come out with results in a little while from now. CNBC-TV18's research Sunita Nagpal discusses what one can expect form it.

According to CNBC-TV18's earnings estimates, Ranbaxy's Q3CY06's gross revenues are estimated to be up 2.44% from Rs 1303.9 crore to Rs 1596.5 crore. The company is estimated to make net profit of Rs 179.15 crore versus Rs 18.4 crore. Also, EBITDA margin is estimated at 19% in Q3 versus 18% in Q2.

Ranbaxy's revenue growth would be led by the 180-day exclusivity of generic Zocor 80mg and Terapia acquisition. The company's US revenues are estimated at USD 110 million, which includes about USD 20 million from generic Zocor (one week impact).